Multiple mechanisms underlie resistance of leukemia cells to Apo2 Ligand/TRAIL
Jinrong Cheng(Roswell Park Comprehensive Cancer Center), Elizabeth A. Repasky(Roswell Park Comprehensive Cancer Center), Maria R. Baer(University of Maryland, Baltimore), Bonnie L. Hylander(Roswell Park Comprehensive Cancer Center), Xing Chen(Harbin Medical University)
Cited by 70
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
|Journal of Clinical Oncology|2010|764